NDC 0006-3516-59 Primaxin IV

Imipenem And Cilastatin Sodium

  1. Labeler Index
  2. Merck Sharp & Dohme Corp.
  3. 0006-3516
  4. NDC Code: 0006-3516-59 Primaxin IV

NDC Package Code 0006-3516-59

The NDC Code 0006-3516-59 is assigned to a package of 25 vial, single-dose in 1 tray > 100 ml in 1 vial, single-dose of Primaxin IV, a human prescription drug labeled by Merck Sharp & Dohme Corp.. The product's dosage form is injection, powder, for solution and is administered via intravenous form.

Field Name Field Value
NDC Code 0006-3516-59
Package Description 25 VIAL, SINGLE-DOSE in 1 TRAY > 100 mL in 1 VIAL, SINGLE-DOSE
Proprietary Name Primaxin IV What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name Imipenem And Cilastatin Sodium What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
Drug Uses This medication is used to treat a wide variety of bacterial infections. This medication is known as a carbapenem-type antibiotic. It works by stopping the growth of bacteria.
11-Digit NDC Billing Format 00006351659 NDC Format for Billing
For insurance billing purposes the Centers for Medicare & Medicaid Services (CMS) created an 11 digit NDC derivative identifier. If the NDC Package code is less than 11 digits the code must be padded with leading zeros. The leading zeros must be added to the appropriate segment to create a 5-4-2 configuration.
Billing Unit EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Product Type Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Labeler Name Merck Sharp & Dohme Corp.
Dosage Form Injection, Powder, For Solution - A sterile preparation intended for reconstitution to form a solution for parenteral use.
Administration Route(s)
  • Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
  • IMIPENEM 500 mg/100mL
  • CILASTATIN SODIUM 500 mg/100mL
Pharmacological Class(es)
  • Carbapenems - [CS]
  • Penem Antibacterial - [EPC] (Established Pharmacologic Class)
  • Dipeptidase Inhibitors - [MoA] (Mechanism of Action)
  • Renal Dehydropeptidase Inhibitor - [EPC] (Established Pharmacologic Class)
Sample Package No Sample Package?
This field Indicates whether this package is a sample packaging or not.
Marketing Category NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number NDA050587 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Start Marketing Date 11-26-1985 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.
Listing Expiration Date 12-31-2021 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.
Exclude Flag N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

NDC Code Structure

  • 0006 - Merck Sharp & Dohme Corp.
    • 0006-3516 - Primaxin
      • 0006-3516-59 - 25 VIAL, SINGLE-DOSE in 1 TRAY

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

NDC HCPCS Crosswalk

This crosswalk is intended to help the public understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes.

NDC 0006-3516-59 HCPCS crosswalk information with package details and bill units information.

NDC Billing CodeHCPCS CodeHCPCS Code Desc.DosagePackage SizePackage QuantityBillable UnitsBillable Units / Pkg
00006351659J0743Cilastatin sodium injection250 MG125250

* Please review the disclaimer below.